|
For Immediate Release
November 19, 2001
(Washington, DC) - The Aspirin Foundation of America (AFA) today welcomed new research demonstrating that aspirin is as effective as warfarin in protecting patients against recurrent ischemic stroke.
The research was led by Dr. J.P. Mohr of Columbia University in New York and involved more than 2,200 patients. The study, which was published in the November 15 issue of the New England Journal of Medicine, found that over the course of two years, nearly 18 percent of the patients taking warfarin died or had another ischemic stroke, compared with 16 percent of patients taking aspirin. The aspirin dosage studied was 325 mg daily.
"We are pleased that aspirin, which has proven to be effective in the treatment of heart disease and so many other indications, has again been found to protect against serious illness," said Dr. Thomas Bryant, AFA president. "Aspirin therapy is a safe and effective regimen for most people and is far less costly than other therapies," he said, noting that a year's supply of aspirin costs approximately $10, compared with prescription drugs which can cost $300 per year.
As with any medication, the AFA strongly recommends those considering aspirin therapy to consult with their physicians.
###
Contact:
Caroline Perrin
807 National Press Building, Washington, DC 20036
Phone: 800-432-3247 Fax: 202/737-8406
info@aspirin.org
|
